Newly filed disclosures show that CEO Dr. Vlad Vitoc and other board members acquired approximately 182,445 shares between November 21 and 28, 2025. The latest insider buying arrives as ateganosine continues to deliver encouraging results. These outcomes have strengthened internal and external confidence that MAIA‘s novel telomere-targeting approach may represent a meaningful new therapeutic pathway for patients with advanced non-small cell lung cancer.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAIA:
- MAIA Biotechnology Advances NSCLC Treatment with Ateganosine
- MAIA Biotechnology announces open market purchases by CEO, directors
- MAIA Biotechnology Highlights Ateganosine Progress at SITC 2025
- MAIA Biotechnology highlights momentum of ateganosine clinical program
- MAIA Biotechnology Expands Phase 2 Study in Romania